Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year
survival rate of approximately 60%. Despite advances in therapy, patients experience cycles …

Deriving disease subtypes from electronic health records (EHRs) can guide next-generation
personalized medicine. However, challenges in summarizing and representing patient data …

Importance Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in
patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an …

Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM),
with safety profiles varying across drug classes and across agents within the same class …

Anti-CD38 monoclonal antibody (MoAb) treatments including daratumumab (DARA) are
effective therapies for both newly diagnosed and relapsed multiple myeloma (MM). In this …

Background Concern has been increasing in oncology regarding randomized clinical trial
(RCT) eligibility limiting the generalizability of the findings to real-world populations. Using a …

Bone disease is the most frequent complication in multiple myeloma (MM) resulting in
osteolytic lesions, bone pain, hypercalcemia and renal failure. In MM bone disease the …

Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for
improved imaging methods and therapeutics. Recently, we identified CD46 as an …

Although current treatments are effective in controlling multiple myeloma (MM) and
prolonging remission, the disease invariably recurs. A possible explanation for the …

Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the
pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective, potent, oral …